MINNEAPOLIS--(BUSINESS WIRE)--Inspire Medical Systems, the leading developer of neurostimulation therapies for the treatment of obstructive sleep apnea (OSA), announced today The STAR trial (Stimulation Therapy for Apnea Reduction), evaluating both the safety and effectiveness of Inspire™ Upper Airway Stimulation (UAS) therapy, is currently underway at 9 leading medical centers across the United States and at 4 sites in Europe. In addition, several OSA patients have already been implanted with Inspire therapy in The STAR trial.
